CIK 0001724521
- Large accelerated filer
Arcus Biosciences, Inc.
Sign in to watch- Ticker
- RCUS
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 473898435
- Phone
- +1 510-694-6200
- Business address
- 3928 POINT EDEN WAY, HAYWARD, CA, 94545
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $84,810
- in 1 filing, $85K under 10b5-1 plans
Net −$84,810. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-11 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −7,763 | $25.63 | $199K | 84,161 |
| 2026-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +24,000 | 91,924 | ||
| 2026-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +96,000 | 96,000 | ||
| 2025-12-31 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −6,552 | $23.38 | $153K | 67,924 |
| 2025-12-17 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −5,960 | $22.16 | $132K | 74,476 |
| 2025-12-16 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −6,702 | $21.88 | $147K | 80,436 |
| 2025-11-26 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −5,000 | $25.00 | $125K | 87,138 |
| 2025-10-28 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −5,000 | $20.00 | $100K | 92,138 |
| 2025-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +37,000 | 97,138 | ||
| 2025-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-12-31 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −3,594 | $15.00 | $54K | 60,138 |
| 2024-12-15 | Goeltz II Robert C. Chief Financial Officer | Shares withheld for taxes | −10,099 | $16.08 | $162K | 63,732 |
| 2024-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +22,000 | 73,831 | ||
| 2024-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +21,300 | 73,131 | ||
| 2024-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +86,600 | 86,600 | ||
| 2024-01-02 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −2,004 | $20.00 | $40K | 51,831 |
| 2023-12-19 | Goeltz II Robert C. Chief Financial Officer | Returned to the company 10b5-1 | −2,808 | $18.09 | $51K | 53,835 |
| 2023-12-18 | Goeltz II Robert C. Chief Financial Officer | Returned to the company 10b5-1 | −2,749 | $17.74 | $49K | 56,643 |
| 2023-06-07 | Goeltz II Robert C. Chief Financial Officer | Sale 10b5-1 | −4,049 | $20.04 | $81K | 59,392 |
| 2023-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +34,000 | 63,441 |
Page 1 of 2 · 33 trades